Bacterial Conjunctivitis
📧 Sign up to get email alerts when something new happens for Bacterial Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-08-16FDA Approved: BESIVANCE — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for BESIVANCE (besifloxacin) submitted by Bausch & Lomb Americas Inc.
-
FDA approval · 2013-05-10FDA Approved: BESIVANCE — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approves a supplemental application for BESIVANCE (besifloxacin) submitted by Bausch & Lomb Americas, updating the drug’s labeling throu…
-
CLINICAL_TRIALS trial_result · 2013-05-01Clinical Trial Update: Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle [Phase 3]
A Phase 3 safety study comparing Besivance (besifloxacin ophthalmic suspension) 0.6% to vehicle in bacterial conjunctivitis, with results po…
-
FDA approval · 2013-04-29FDA Approved: OFLOXACIN OPHTHALMIC — Original Application (Altaire Pharmaceuticals Inc.)
FDA approved Altaire Pharmaceuticals' OFLOXACIN OPHTHALMIC (ofloxacin ophthalmic solution) through an Original Application (ANDA).
-
FDA approval · 2013-03-12FDA Approved: AZASITE — Supplemental Application (Thea Pharma Inc.)
The FDA approved a supplemental application for AZASITE (azithromycin monohydrate ophthalmic solution) submitted by Thea Pharma Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2012-12-18FDA Approved: MAXITROL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for MAXITROL, a combination ophthalmic solution containing neomycin sulfate, polymyxin B sulfate…
-
FDA label_change · 2012-12-10FDA Approved: MAXITROL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for MAXITROL, a combination ophthalmic antibiotic/steroid, submitted by Novartis Pharmaceuticals…
-
FDA approval · 2012-10-02FDA Approved: LOTEPREDNOL ETABONATE AND TOBRAMYCIN — Supplemental Application (Bausch & Lomb Americas Inc.)
The FDA approved a supplemental application for the Loteprednol etabonate and tobramycin ophthalmic suspension by Bausch & Lomb Americas Inc…
-
CLINICAL_TRIALS trial_result · 2012-03-29Clinical Trial Update: Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis [Phase 2, Phase 3]
Phase 2/3 clinical trial update reports efficacy results for besifloxacin ophthalmic suspension in the treatment of bacterial conjunctivitis…
-
CLINICAL_TRIALS trial_result · 2011-12-09Clinical Trial Update: Systemic Pharmacokinetics of BOL-303224-A [Phase 1]
Phase 1 trial update reports systemic pharmacokinetics data for BOL-303224-A in bacterial conjunctivitis.
-
CLINICAL_TRIALS withdrawal · 2011-12-01Clinical Trial Update: Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis [Phase 2]
A Phase 2 trial evaluating AL-15469A 0.5% / AL-6515 0.3% ophthalmic suspension for bacterial conjunctivitis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2011-11-30Clinical Trial Update: A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis [Phase 3]
Phase 3 clinical trial evaluating the safety and efficacy of gatifloxacin ophthalmic solution for bacterial conjunctivitis, with results pos…
-
CLINICAL_TRIALS trial_result · 2011-11-30Clinical Trial Update: A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis [Phase 3]
Phase 3 trial evaluating gatifloxacin for safety and efficacy in bacterial conjunctivitis completed with posted results.
-
CLINICAL_TRIALS trial_result · 2011-10-27Clinical Trial Update: Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) [Phase 3]
A Phase 3 trial evaluating AzaSite (azithromycin ophthalmic solution) versus vehicle for bacterial conjunctivitis has completed and results …
-
CLINICAL_TRIALS trial_result · 2011-10-27Clinical Trial Update: Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) [Phase 3]
Phase 3 trial comparing AzaSite (azithromycin ophthalmic solution) to tobramycin for bacterial conjunctivitis assessed clinical and microbia…
-
FDA approval · 2011-10-07FDA Approved: VIGAMOX — Supplemental Application (Harrow Eye, LLC)
The FDA approved a supplemental application for VIGAMOX (moxifloxacin hydrochloride) submitted by Harrow Eye, LLC.
-
CLINICAL_TRIALS trial_result · 2011-09-21Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis [Phase 4]
This is a Phase 4 clinical trial evaluating gatifloxacin for bacterial conjunctivitis. The study has completed and results were posted in 20…
-
CLINICAL_TRIALS trial_result · 2011-03-22Clinical Trial Update: Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis [Phase 3]
Phase 3 clinical trial update for moxifloxacin ophthalmic solution in bacterial conjunctivitis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2010-10-25Clinical Trial Update: Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis [Phase 3]
Phase 3 clinical trial evaluating the efficacy of Maxinom and Maxitrol in reducing signs and symptoms of acute bacterial conjunctivitis.
-
CLINICAL_TRIALS trial_result · 2010-10-25Clinical Trial Update: Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis [Phase 3]
Phase 3 clinical trial evaluating the effectiveness of TOBRACORT versus TOBRADEX for reducing the signs and symptoms of acute bacterial conj…
-
FDA approval · 2010-08-03FDA Approved: TOBRADEX ST — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for TOBRADEX ST (tobramycin/dexamethasone) from Harrow Eye, LLC.
-
FDA approval · 2010-06-03FDA Approved: LOTEPREDNOL ETABONATE AND TOBRAMYCIN — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for Loteprednol etabonate and tobramycin, expanding labeling to treat inflammatory ocular conditions…
-
FDA approval · 2010-05-18FDA Approved: ZYMAXID — Original Application (Allergan, Inc.)
FDA approved ZYMAXID (gatifloxacin) through Allergan's original NDA for the treatment of bacterial conjunctivitis.
-
CLINICAL_TRIALS trial_result · 2010-03-31Clinical Trial Update: Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment [Phase 4]
Phase 4 clinical trial update examining progression of bacterial conjunctivitis symptoms during antibiotic treatment.
-
CLINICAL_TRIALS trial_result · 2010-02-02Clinical Trial Update: Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora [Phase 4]
Phase 4 clinical trial assessing a topical antibacterial treatment for bacterial conjunctivitis and its effect on ocular microbial flora; re…